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A  continuous  precipitation-based  capture  step  for recombinant  monoclonal  antibodies  (mAbs)  has  been
developed  using  polyethylene  glycol  (PEG)  in  a  sequential  precipitation  approach.  In the  ﬁrst  step,  impu-
rities are  removed  by precipitation  at low  pH  and  low  PEG  concentrations.  After removing  the  precipitate,
mAbs  are  precipitated  by pH adjustment  and  PEG  supplementation.  Yields  of  86–94% and  a reduction
in  host  cell  proteins  (HCPs)  to  7200–15,000  ppm  were reached  depending  on the  mAb.  Host  cell  DNA
was  removed  to 18–29  ng/ml,  which  was  independent  of  the  starting  DNA  concentration.  The  secondary
structure  and isoform  distribution  of  mAbs  are  unaltered  compared  with  the  chromatographically  puri-
ﬁed  reference  material.  The  method  was  then  shifted  to a continuous  operating  mode  in a  single-useapture
ollow ﬁber
tubular  reactor  by converting  the  time  to  reach  equilibrium  into  residence  time.  Tangential  ﬂow  ﬁltra-
tion  (TFF)  has  been  used  as an  alternative  precipitate  capture  step  to centrifugation.  The  yield  was  not
compromised  with  the  use  of  TFF  (>92%),  and  impurity  removal  was  even  enhanced  compared  with  cen-
trifugation.  Concentration  of the  mAb  precipitate  by  TFF  and  washing  by diaﬁltration  preserves  the  ﬂoc
structure  of  the  precipitate,  thereby  accelerating  the  subsequent  resolubilization.
ublis©  2015  The  Authors.  P
. Introduction
In recent years, polyethylene glycol (PEG) precipitation has
eceived renewed research interest, especially in the ﬁeld of mon-
clonal antibody (mAb) puriﬁcation [1–3]. PEG precipitation is a
imple method that operates at ambient temperature and exhibits
ast precipitation kinetics. Furthermore, PEG precipitation supports
ontinuous production, an operating mode that is progressively
eing introduced into the biopharmaceutical industry, as it is more
conomical and permits the use of single-use equipment at a
maller scale [4].
In recent years, various kinds of precipitation and aqueous two-
hase extraction systems have been investigated as alternatives to
xisting technologies such as chromatography [5–12]. PEG precip-
tation is the most prominent precipitation method for mAbs. A
igh-yield step that offers a relatively low selectivity, PEG precipi-
Abbreviations: CCCS, clariﬁed cell culture supernatant; CD, circular dichroism;
HO, Chinese hamster ovary; CIP, cleaning in place; HCP, host cell proteins; HF,
ollow ﬁber; HMWI,  high molecular weight impurities; LMH, L/m2/h; PBS, phos-
hate buffered saline; PEG, polyethylene glycol; TFF, tangential ﬂow ﬁltration; TMP,
ransmembrane pressure.
∗ Corresponding author at: Department of Biotechnology, University of Natural
esources and Life Sciences Vienna, Muthgasse 18, A-1190 Vienna, Austria.
E-mail address: alois.jungbauer@boku.ac.at (A. Jungbauer).
ttp://dx.doi.org/10.1016/j.procbio.2015.11.032
359-5113/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tation is most often used as an initial capture step, which involves
precipitation of the product, that is, mAbs or other molecules such
as botulinum toxin B [1,2,9,13–15]. Giese et al. have also assessed
PEG precipitation for impurity precipitation [16]. Product precipita-
tion has the beneﬁt of pool volume reduction during the precipitate
resolubilization. However, it is technically more challenging than
impurity precipitation, as the formed precipitate cannot simply be
removed and discarded, but it has to be resolubilized. In classical
PEG precipitation approaches that attempt to directly precipitate
the product out of the clariﬁed cell culture solution, especially large
contaminants such as DNA are inadvertently coprecipitated with
the product. Therefore, the burden on the subsequent puriﬁcation
steps is increased [13]. In order to reduce contaminants that would
coprecipitate in the second step, an additional precipitation step
can be introduced prior to the actual product precipitation. Caprylic
acid precipitation and CaCl2 ﬂocculation have been investigated
for this purpose [9,14,17,18]. Contaminant reduction can also be
integrated into the cell harvest step by adding ﬂocculants [19–21].
Although these approaches are feasible, their disadvantages com-
plicate the process scheme and introduce additional substances
into the process, which must be removed.Most publications on PEG precipitation are focused on the actual
product precipitation and parameter optimization. However, the
crucial precipitate capture step is not addressed. Centrifugation
is tacitly assumed to be suitable for this purpose. Solid–liquid
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Flowchart of the experimental setup for continuous sequential precipitation includ
(CCCS)  is supplemented by different stock solutions. Mixing is accomplished using helica
by  depth ﬁltration. In the second step (B), the mAb  is precipitated. In the third step (C), th
Table 1
Titer, isoelectric points, and impurity levels of investigated IgG supernatants pro-
duced in CHO cell culture.
mAb1 mAb2 mAb3
pI 9.3 8.2 7.6
Titer (mg/ml) 2.3 4.9 2.9
DNA (ng/ml) 5411 2278 806
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experiments were performed in 96-well DeepWell plates (Nunc,HCP (ppm) 101,688 96,087 113,538
eparation can be achieved using centrifugation because of the den-
ity difference of the precipitate and the mother liquor. However,
lthough the method of choice for laboratory-scale experiments,
entrifugation has some decisive drawbacks in the context of
rotein precipitation, especially at a large scale. During the cen-
rifugation process, the precipitate ﬂocs are compacted to a dense,
aste-like mass. Resolubilization of the pellet is a slow process
in the order of hours) with a variability in the processing time.
igh capital investment, maintenance efforts, and low ﬂexibility
re additional disadvantages of centrifugation. Kuczewski et al.
emonstrated the suitability of tangential ﬂow ﬁltration (TFF) as a
recipitate capture step in a feasibility study of an extremely high-
iter mAb  [2]. The precipitate is ﬁrst concentrated in the retentate,
ashed by diaﬁltration, and ﬁnally dissolved. Unlike in centrifu-
ation, the individual ﬂocs are preserved during TFF. These ﬂocs
xhibit rapid dissolution kinetics.
This work addresses some of the limitations of classical PEG
recipitation. A sequential PEG precipitation-based capture step
or mAb  puriﬁcation that solely relies on PEG addition and pH
djustment is presented. In a ﬁrst step, impurities are precipitated
nd in the second step, the product is precipitated. This sequen-
ial approach circumvents the problem of coprecipitating DNA and
hows increased host cell protein (HCP) removal. The starting point
or the development of the sequential precipitation approach was
he display of the lowest solubility of proteins at or near their
I, where the net charge is zero and repulsion therefore mini-
ized. While the majority of CHO HCPs and DNA have isoelectric
oints in the acidic pH range, recombinant antibodies typically have
soelectric points at neutral or basic pH [22,23]. The sequential pre-
ipitation method was optimized for three recombinant antibodies
f varying titers and isoelectric points (pIs) (see Table 1) in the batch
ode; further, this was shifted to the continuous mode for one
Ab  (mAb3) as proof of concept. In addition, TFF with hollow-ﬁber
HF) modules was  used as a precipitate capture step. TFF is a well-ing discontinuous precipitate recovery by TFF. The clariﬁed cell culture supernatant
l-type static mixers. In the ﬁrst step (A), impurities are precipitated and removed
e mAb  precipitate is concentrated in the retentate before being dissolved.
established technology with the advantages of a linear scale-up
behavior and a single-use setup, thereby minimizing cleaning and
validation efforts and eliminating the risk of cross contamination
[24,25].
For feasible screening efforts in this study, the parameters for
screening were kept to a minimum. Conductivity, PEG size, PEG
concentration, and pH inﬂuence the PEG precipitation of proteins.
The inﬂuence of conductivity was  not screened for, as the aim of
this study was to precipitate mAbs out of crude clariﬁed cell cul-
ture supernatant (CCCS) with a predeﬁned conductivity. It is well
known that PEGs with higher molecular weight are more efﬁcient
up to about PEG6000, that is, lower concentrations are required for
precipitation [26,27]. However, the higher efﬁciency is accompa-
nied by higher viscosity [28]. Therefore, PEG6000 was selected, as
it has been used in previous studies for precipitation at similar mAb
titers with high efﬁciency and acceptable viscosities [1,9,14].
2. Materials and methods
2.1. Materials
2.1.1. Feed stocks
Clariﬁed CHO cell culture supernatants of the three IgG1 were
provided by Novartis AG (mAb1 and mAb2) (Basel, Switzerland)
and by Sandoz (mAb3) (Kundl, Austria). The supernatant character-
istics are presented in Table 1. Supernatants were stored at −20 ◦C
for the long term or at 4 ◦C for the short term.
2.1.2. Reagents
All chemicals were of analytical grade and were purchased
either from Sigma–Aldrich (St. Louis, MO,  USA) or from Merck Mil-
lipore (Darmstadt, Germany), unless otherwise stated.
2.2. Methods
2.2.1. PEG precipitation
PEG6000 stock solutions (45 w/v%) were prepared in 25 mM
buffer and 150 mM NaCl, and these were set to the desired pH
range of 3.5–8.5. The solubility curves of mAbs, the optimization
of host cell DNA removal, and the mAb  precipitation screeningRoskilde, Denmark). The ﬁnal working volume was 1.2 ml.  The
buffer, PEG6000 stock solution, and CCCS were mixed to screen dif-
ferent PEG concentrations at constant antibody concentrations. The
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mig. 2. (A) PEG precipitation screening in a pH range of 3.5–5.5 for DNA removal. T
hree  mAbs at a pH range of 6.5–8.5. (For interpretation of the references to color in
lates were sealed and incubated on a rotator (Stuart, Stone, UK) at
5 rpm for 2 h to reach equilibrium conditions. The precipitate was
ollected by centrifugation at 4000 × g for 20 min. The supernatants
ere discarded and pellets dissolved in phosphate-buffered saline
PBS). All experiments were performed at room temperature. Citric
cid solution (3 M)  was used to lower the pH to the desired level
or removing contaminants, unless otherwise stated.
.2.2. Continuous PEG precipitation
Continuous PEG precipitation was performed in a simple tubu-
ar reactor (ID: 4.8 mm,  Tygon tubing R-3603 from IDEX, Wertheim,
ermany) equipped with polypropylene Kenics-type, helical static
ixers (Stamixco, Winterthur, Switzerland). The reactor length
as 13.5 m to ensure a mean residence time of 15 min  at a linear
ow rate of 1.5 cm/s. PEG6000 stock solutions (45 w/v%) at the opti-
ized precipitation pH were added to the CCCS, and 25% HCl and
0 M NaOH were used to adjust the pH. Peristaltic pumps (Reglo
igital, Ismatec, IDEX, Wertheim-Mondfeld, Germany) were used
or pumping all solutions. Precipitated impurities were removed
y 1.0/0.3 m depth ﬁltration in the ﬁrst step (Sartoclear P, Sarto-
ius, Göttingen, Germany). A schematic ﬂowchart of the continuous
recipitation setup is depicted in Fig. 1A and B.
.2.3. Precipitate recovery by centrifugation
Antibody precipitate was recovered by centrifugation using a
ultifuge X3-FR (Thermo Scientiﬁc, Waltham, MA,  USA) at 3000 rcf
or 15 min  at room temperature. After centrifugation, the super-
atant was discarded and the precipitate pellet was dissolved in
hosphate buffered saline (PBS) if not stated otherwise. Pellets
ere dissolved on a rotator at 30 rpm overnight.
.2.4. Precipitate recovery by TFF
A simple TFF system with minimal dead volume was custom-
uilt. A Masterﬂex peristaltic pump (Cole-Parmer, Vernon Hills, IL,
SA) was used as a recirculation/feed pump. A peristaltic pump
IPC, Ismatec, IDEX, Wertheim-Mondfeld, Germany) was used to
ontrol the permeate ﬂux. The permeate ﬂux was set by the per-
eate pump ﬂow rate and measured by collecting the permeatest performing conditions are marked in red and green (B) Solubility curves of the
gure legend, the reader is referred to the web  version of this article.)
on a scale (Sartorius, Göttingen, Germany). Feed, retentate, and
permeate pressures were monitored using pressure sensors (Pen-
doTECH, Princeton, NJ, USA). The TFF setup is depicted in Fig. 1C.
The pressure and permeate ﬂux data were collected using Lab-
View (National Instruments, Austin, TX, USA). HF microﬁltration
cartridges (0.1-, 0.2-, and 0.45-m pore size, and 110 cm2 surface
area) were obtained from GE Healthcare (GE, Uppsala, Sweden). HF
membrane regeneration was  performed on an Äkta Crossﬂow. The
membrane was ﬂushed with water for 60 min, followed by 60 min
of cleaning in place (CIP) with 0.25 M NaOH. A water ﬂux test was
conducted to ensure membrane integrity. Sodium phosphate buffer
set to the pH used for precipitation and supplemented with 14 w/v%
PEG6000 (optimized PEG concentration for mAb  precipitation) was
used for system equilibration and diaﬁltration. Concentrated anti-
body precipitate was dissolved by dilution in PBS to about 10 mg/ml
if not stated otherwise.
2.2.5. Protein A afﬁnity chromatography
Amsphere protein A JWT203 resin (JSR Micro, Sunnyvale, CA,
USA) was  used for the preparative puriﬁcation of all three antibod-
ies on an Äkta Pure workstation (GE Healthcare, Uppsala, Sweden).
PBS was  used as an equilibration buffer. The column wash con-
sisted of three steps (5 column volumes (CV) of equilibration buffer,
5CV of equilibration buffer supplemented with 1 M NaCl, and 5CV
equilibration buffer). Elution was performed with 100 mM sodium
acetate at a pH of 3.1. NaOH (250 mM)  was used for CIP between
runs. Four different buffers (sodium citrate, sodium acetate (both
pH 5.3), sodium phosphate (pH 7.5), and Tris (pH 8.1)) at three
conductivities each (2.5, 7.5, and 15.0 mS/cm) were tested for pre-
cipitate dissolution. Buffers of 50-mM concentration were prepared
and set to the respective conductivities at 20 ◦C using either satu-
rated NaCl (in the respective buffers) or HQ-H2O.
2.3. Analytical methods2.3.1. Protein A afﬁnity chromatography
The mAb  concentrations were determined using analytical pro-
tein A afﬁnity chromatography, as described in Ref. [29], using
an n-protein A CIMdisk monolithic column (BIA Separations,
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Table 2
Yield and impurity levels achieved using classical and sequential PEG precipitation.
mAb  precipitate was recovered by centrifugation in both precipitation approaches.
Data are given as mean ± standard deviation in the case of triplicate analysis.
Yield (%) Classical PEG precipitation Sequential PEG precipitation
mAb1 90 ± 2 92 ± 2
mAb2 88 ± 2 86 ± 3
mAb3 91 ± 1 94 ± 2
DNA (ng/ml)
mAb1 5113 ± 261 29 ± 4
mAb2 2155 ± 152 18 ± 3
mAb3 678 ± 89 28 ± 7
HCP (ppm)
mAb1 54,077 ± 4512 15,072 ± 3164
mAb2 37,399 ± 2353 10,042 ± 1571
mAb3 19,953 ± 2691 10,992 ± 3405
HMWI  (%)
mAb1 1.2 ± 0.1 0.9 ± 0.1Fig. 3. Effect of dosage time of PEG addition on mAb  yield for mAb3.
jdovcina, Slovenia). The equilibration and wash buffer consisted
f 30 mM sodium phosphate and 1 M NaCl at pH 7.4 and the elution
uffer was 10 mM HCl at pH 2.0.
.3.2. Size-exclusion chromatography
High molecular weight impurities (HMWI) were determined by
ize-exclusion chromatography using a TSKgel G3000SWxl column
Tosoh Bioscience, Minato, Japan). Potassium phosphate (150 mM)
t pH 6.5 was used as the mobile phase at a ﬂow rate of 0.4 ml/min.
.3.3. DNA concentration determination
The concentrations of double-stranded DNA (dsDNA) were mea-
ured with a Quant-iT Picogreen dsDNA assay kit (Life Technologies,
arlsbad, CA, USA), according to the manufacturer’s instructions,
n a 96-well format. In brief, 1:2 serial dilutions of samples and 
NA standard were performed in a 96-well plate in 1 × TE buffer
10 mM Tris–HCl, 1 mM  ethylenediaminetetraacetic acid (EDTA),
H 7.5). Approximately 100 l of each dilution was transferred to a
uorescent black-bottom 96-well plate, 100 l of pre-diluted color
eagent was added, and the signal intensities were measured in a
late reader. The excitation and emission wavelengths were 480
nd 520 nm,  respectively.
.3.4. CHO HCP ELISA
Goat anti-CHO HCP antibody (3G-0016-AF, Cygnus, Southport,
C, USA) was used to coat MaxiSorp Immuno 96-well plates (NUNC,
oskilde, Denmark). Blocking was carried out by incubation with
% bovine serum albumin (BSA, Sigma Aldrich) in Tris-buffered
aline (TBS). A standard curve was prepared in duplicate with a CHO
CP standard (F553H, Cygnus). Samples and the pre-diluted CHO
CP standard were serially diluted at 1:2 with 1% BSA in TBS and
ransferred to the measurement plate. The goat anti-CHO HCP anti-
ody conjugated to HRP (1:2,000 diluted in 1% BSA in TBS + 0.05%
ween 20) was used as the detection antibody. The TMB  Peroxidase
IA Substrate Kit (Bio-Rad, Hercules, USA) was used for staining.
he enzymatic reaction was stopped with 1 N sulfuric acid. The
bsorbance at 450 nm was measured using a Tecan F500 Inﬁnite
late reader (Tecan, Maennedorf, Switzerland).
.3.5. Circular dichroism spectroscopy
Samples were buffer-exchanged into 5 mM NaPO4 of pH 7.2
sing Amicon centrifugal ﬁlter units (100-kDa MWCO) immedi-
tely before circular dichroism (CD) measurements. A Chirascan CD
pectrometer (Applied Photophysics, Leatherhead, UK) was  used to
ecord the CD spectra from 180 to 260 nm in a 1-mm quartz cuvette.
 bandwidth of 1 nm and a time constant of 1 s were used.mAb2 4.0 ± 0.1 3.9 ± 0.2
mAb3 3.9 ± 0.2 3.8 ± 0.1
3. Results and discussion
3.1. Contaminant removal at low pH
The precipitation screenings were performed in 96-well Deep-
Well plates to keep the sample consumption to a minimum while
also minimizing errors due to small volumes. PEG concentration
and pH have been used as sole screening parameters for both pre-
cipitation steps. The results of the screening experiments for both
precipitation reactions, the impurity as well as the mAb  precipita-
tion, are shown in Fig. 2A and B, respectively.
For the impurity precipitation, a pH range of 3.5–5.5 was
screened. The soluble DNA concentration is signiﬁcantly reduced
by pH reduction alone (Fig. 2A). Addition of PEG6000 at low concen-
trations is sufﬁcient to reduce the DNA concentration to minimal
levels. DNA precipitation was  most efﬁcient at pH 4.0–4.5. How-
ever, at a pH above or below this level, signiﬁcantly higher PEG6000
concentrations were needed to achieve DNA reduction to similar
levels. HCPs were also removed to some extent due to the pH reduc-
tion, but addition of PEG6000 up to 7 w/v% did not reduce them
further (data not shown). Higher concentrations of PEG resulted in
signiﬁcant loss of mAbs due to precipitation. From the screening
results, a pH of 4.0 and 3 w/v% PEG6000 were selected as the opti-
mal  conditions for impurity removal for all three antibodies. This
step appears to be a promising platform approach, as the DNA of
different cell lines is likely to behave very similar, unrelated to the
product.
For mAb  precipitation in the second step, as expected, the low-
est PEG concentration needed for efﬁcient precipitation was found
to be close to the respective pI for all three antibodies (Fig. 2B). As its
feasibility was proven, sequential PEG precipitation was  compared
with classical PEG precipitation, that is, mAb  precipitation without
prior impurity precipitation (see Table 2). The second precipita-
tion step did not deteriorate the ﬁnal mAb  yield. DNA is reduced
to very low levels in the sequential approach while being undesir-
ably coprecipitated in classical PEG precipitation. HCP removal is
also enhanced by a factor of 1.8–3.7 in the sequential approach
depending on the mAb. The HMWI  levels were similar for both
precipitation methods.
The dosage time of the PEG stock solution to reach the ﬁnal PEG
concentration was  investigated. The direct addition of solid PEG
ﬂocs was also investigated. Here, the PEG ﬂocs dissolved within
about 6 min  under stirring. Single-step PEG addition and solid PEG
addition show similar equilibrium yields, whereas slowly adding
PEG over 10 min  signiﬁcantly reduced the mAb  yield (see Fig. 3).
N. Hammerschmidt et al. / Process Biochemistry 51 (2016) 325–332 329
Fig. 4. (A) Speed of DNA precipitation and mAb  yield in the low-pH step (pH4/3 w/v%
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Table 3
Comparison of batch and continuous PEG precipitation of mAb3 using centrifugation
for precipitate recovery. Data are given as mean ± standard deviation in the case of
a  triplicate analysis.
Batch precipitation Continuous precipitation
Yield (%) 94 ± 2 92 ± 1
HCP (ppm) 10,992 ± 3405 10,541 ± 2949
DNA (ppm) 17 ± 3 22 ± 5
HMWI  (%) 3.8 ± 0.1 3.8 ± 0.2
Table 4
HF membrane cartridge performance test: Normalized water and 14 w/v% PEG6000
permeability.
Pore size (m) Normalized water
permeability (LMH)
Normalized PEG
permeability (LMH)
0.1 706 120
the HF with 0.1-m pore size was ruled out due to the insufﬁ-
cient ﬂuxes resulting in low throughput and long runtimes or an
excessively large ﬁlter area.EG6000) and (B) mAb yield in the second step (pH 7.5/14 w/v% PEG) for mAb3 as a
unction of incubation time. Point 0 min  was  deﬁned as the time point at which the
ample and PEG stock solution were completely mixed.
hese ﬁndings indicate that continuous precipitation with only one
oint of PEG addition, that is, reaching the ﬁnal PEG concentration
mmediately, is not only possible but also favorable, as higher yields
re obtained by rapid addition of PEG.
The feasibility of precipitation in the continuous mode is also
igniﬁcantly determined by a second factor, the speed of the pre-
ipitation reaction. Fast precipitation kinetics directly translate into
hort required residence times and thus to short tubular reactor
engths. The speed of DNA precipitation in the low-pH step and mAb
recipitation in the second step was investigated for mAb3. In both
ases, the precipitation reactions were very fast and completed
fter the sample and PEG stock solution were mixed completely
see Fig. 4A). These data are in agreement with visual examination.
urbidity increased almost instantaneously after adding PEG6000.
he mAb3 yield was not compromised even at long residence times
t low pH (Fig. 4B).
Based on the results of the kinetics experiments, a residence
ime of 15 min  was selected for the tubular reactors of both precip-
tation steps. A simple tubular reactor was set up with helical-type
tatic mixers, and both precipitation reactions were performed
ontinuously for mAb3. Impurities were removed by normal-ﬂow
ltration between the two precipitation steps.
Samples were drawn during the continuous operation of the IgG
recipitation (second step). The mAb  precipitate was recovered by
entrifugation, and the redissolved samples were analyzed for mAb
ield and impurity (DNA and HCP) levels (see Fig. 5). The process
as performed at steady state for 2 h, with no drift of mAb  yield,
CP, or DNA.
.2. Continuous PEG precipitation
Continuous precipitation performed almost identically to batch
recipitation (Table 3). The mAb  yield was above 90% in both oper-
ting modes. The concentrations of HCPs and DNA could be reduced
o about 10,000 and 20 ppm, respectively. The HMWI  levels were
ot altered by the continuous operating mode.0.2 3362 883
0.45  6472 1253
3.3. Precipitate recovery by TFF
HF microﬁltration membranes were selected, due to their
proven suitability in other ﬁelds with similar processes such as cell
harvest and cell retention in perfusion culture [30,31]. Three dif-
ferent pore sizes were tested in terms of their normalized water
and normalized PEG ﬂuxes. Fluxes of 14 w/v% PEG6000 solution
in 50 mM sodium phosphate and 150 mM NaCl, at pH 7.5, that
is, the PEG concentration used during precipitation, can be used
as a model of the actual sample matrix. The increased viscosity
increases the pressure and lowers the transmembrane ﬂux in the
microﬁltration process. Permeate ﬂux versus transmembrane pres-
sure (TMP) data were collected at different feed ﬂow rates, which
were linearly ﬁtted and extrapolated to the permeability of the
respective solution at a TMP  of 1 bar. For both solutions tested, the
HF membrane with the smallest pore size (0.1 m) yielded much
lower ﬂuxes than the HF membrane with bigger pore size (Table 4).
Interestingly, the water ﬂux of the HF membrane with 0.45-m
pore size is almost double that of the 0.2-m HF membrane while
the ﬂux for the 14 w/v% PEG 6000 solution was only about 40%
higher (883 l/(m2 h) or LMH  vs. 1253 LMH). Based on these results,Fig. 5. Critical quality attributes during steady-state operation of the continuous
PEG precipitation of mAb3. Precipitate recovery was performed by centrifugation.
3 ess Biochemistry 51 (2016) 325–332
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Fig. 6. Inﬂuence of residence time in the TFF system at a shear rate of 1619 s−130 N. Hammerschmidt et al. / Proc
TFF was performed in the constant ﬂux mode, as it has been
eported to minimize fouling [32,33]. The HF membrane with 0.45-
m pore size was ruled out after initial precipitate concentration
rials, as it showed premature blocking of the HF membrane. Differ-
nces in HF membrane structure as well as pore structure are the
ost likely causes for the different behavior. Therefore, concentra-
ion and diaﬁltration runs were performed with HF cartridges with
.2-m pore size. The TMP  stayed constant up to a concentration
actor of about 16 and then started to increase linearly from about
.09–0.32 bar between a concentration factor of 16–50. The concen-
ration was ﬁnished at a concentration factor of 50 (equaling a mAb
recipitate concentration of 100 mg/ml) at which point a retentate
ressure of 1.25 bar was reached. The TMP  decreased slightly dur-
ng the diaﬁltration step to about 0.30 bar. The potential loss of the
rotein precipitate via the passage through the membrane into the
ermeate was evaluated by drawing permeate samples during pre-
ipitate concentration and diaﬁltration. All samples appeared clear
n visual examination with no turbidity at 600 nm,  indicating that
he entire precipitate is rejected by the membrane.
Precipitate recovery by TFF and centrifugation was  compared
see Table 5). Both methods attained the same mAb  yield. TFF gave
 total yield of 92%, comprising step yields of 94% for the precipita-
ion reaction itself and 98% for the recovery from the TFF system.
esidual DNA and HCPs were lower for the TFF recovery; this was
ost likely because washing the precipitate ﬂocs by diaﬁltration is
ore efﬁcient than washing the pelleted precipitate. An increase
n HMWI  levels during TFF recovery was observed, which can be
ttributed to the shear exposure in the HF cartridge. The shear rate
n a circular duct can be calculated (see Eq. (1)), where Q is the vol-
metric ﬂow rate, rﬁber is the radius of the HFs, and n is the number
f ﬁbers in the cartridge [31]:
hear rate = 4 × Q
r3ﬁber × n × 
(1)
he shear rate in the HF cartridge under the selected operating con-
itions (feed ﬂow: 675 LMH, permeate ﬂow: 75 LMH) was 1620 s−1,
s calculated using Eq. (1).
MAb  precipitate was recirculated through the TFF system to
nvestigate the effect of residence time (or cumulative shear expo-
ure) on the HMWI  levels after precipitate dissolution. HMWI
ncreased from 3.6% to 5.4% after 6 h of circulation through the
ystem at a feed ﬂow rate of 675 LMH  (see Fig. 6).
Circular dichroism (CD) spectroscopy has been extensively used
o detect conformational changes in proteins [34–36]. It is used
o detect potential changes in the secondary structure due to the
nterim phase change of the mAb  or the recovery method. Samples
uriﬁed by precipitation and recovered by either centrifugation or
y TFF did not reveal any changes in secondary structure when
ompared to reference material puriﬁed by protein A afﬁnity chro-
atography..4. Dissolution
The dissolution of the concentrated precipitate was tested using
our different buffer substances. Buffer systems spanning a wide pH
able 5
omparison of two different precipitate recovery methods (TFF and centrifugation)
or  mAb3. TFF: The mAb  was concentrated to 100 mg/ml  prior to dissolution. In
oth recovery methods, the mAb was  dissolved to about 10 mg/ml. Data are given
s  mean ± standard deviation for triplicate analysis.
TFF Centrifugation
Yield (%) 92 ± 3 94 ± 2
DNA (ng/ml) 12 ± 6 17 ± 3
HCP (ppm) 7290 ± 1591 10,992 ± 3405
HMWI (%) 4.5 ± 0.2 3.8 ± 0.1on HMWI  levels after resolubilization. The system was ﬁlled with mAb3 precip-
itate at a concentration of 2 mg/ml and recirculated through the system without
concentration.
range with conductivities commonly used in ion exchange and mul-
timodal chromatography, both likely to be subsequent polishing
steps in a full puriﬁcation process, were selected (Fig. 7).
The mAb  precipitate was  concentrated to about 90 mg/ml  in a
0.2-m HF cross-ﬂow ﬁltration module and subsequently diaﬁl-
tered fourfold using 14 w/v% PEG6000 in 25 mM sodium phosphate
and 150 mM  NaCl at a pH of 7.5 prior to dissolution.
For all tested buffers and all conductivities, the mAb yield was
above 90%. The results from the HCP reduction analysis also show
no effect on the dissolution buffer. HCPs can be reduced to below
10,000 ppm for all tested buffers. The HMWI  content of the dis-
solved precipitate was  similar in all investigated buffers (3.7–4.0%).
Only 2.5 mS/cm of Tris–HCl of pH 8.1 shows a markedly lower
HMWI  content than the other buffers. This HMWI  decrease was
not observed for Tris–HCl buffers of higher conductivity. Knevel-
man  et al. have made a similar observation [1]. They found that a
pH above the pI resulted in the highest recovery after resolubiliza-
tion of a PEG precipitated IgG4. However, they did not investigate
the effect of salt concentration or measured HMWI levels.
In general, it is desirable to dissolve the mAb in as high a
concentration as possible to minimize the solution volume. The
concentration of residual PEG after resolubilization of the precip-
itated mAb  by TFF is directly correlated with the dilution factor
during dissolution. After concentration by TFF, the mAb  precip-
itate is dissolved by diluting the precipitant (PEG). The lowest
possible dissolution factor was  determined by dissolving highly
concentrated mAb3 precipitate to different residual PEG6000
concentrations. A linear relationship between dilution factor or
residual PEG concentration and soluble mAb  concentration was
obtained up to a residual PEG concentration of 3 w/v% (black line in
Fig. 8). Below this PEG concentration, the mAb  completely dissolves
and the equilibrium yield is achieved (red line in Fig. 8). Above
this PEG concentration, increasing amounts of the mAb  precipitate
remain undissolved, resulting in lower soluble mAb concentrations
and accompanying decrease in yield.
4. Conclusion and outlook
A sequential PEG precipitation-based capture step for recom-
binant antibodies was  developed in this study. The process was
shown to be feasible for three different antibodies with varying
titers (2.3–4.9 mg/ml) and pI (7.4–9.3) in the batch mode. The
parameters and subunit operations essential to optimizing pro-
cesses for successful implementation were studied. Apart from the
actual precipitation, we  investigated the recovery of antibody pre-
N. Hammerschmidt et al. / Process Biochemistry 51 (2016) 325–332 331
Fig. 7. Twelve different buffers were tested for precipitate dissolution. Approximately 90
dissolved mAb  concentration of 9 mg/ml.
Fig. 8. Soluble mAb  concentration and yield after dissolution of mAb  precipitate as a
function of residual PEG6000 concentration. The mAb  precipitate was concentrated
to about 100 mg/ml  by TFF and diaﬁltered into 50 mM sodium phosphate buffer,
150  mM NaCl, and 14 w/v% PEG6000, at pH 7.5 prior to the dissolution. PBS was
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gure, the reader is referred to the web version of this article.
ipitate as well as its resolubilization. Both aspects that are often
eglected in precipitation research.
A low-pH impurity removal step, the initial step of sequential
recipitation, is a potential platform approach for reducing ini-
ial impurity levels. Technology platforms are in great demand, as
hey are cost-effective and time-saving for developing industrial
rocesses [37]. Transferring the precipitation reaction to the con-
inuous operation mode was demonstrated in a simple, single-use
ubular reactor. Steady-state operation was achieved. Performance
n terms of yield, DNA, and HCP reduction were very similar for
oth batch and continuous operation.
An alternative precipitate recovery step was developed. Con-
entration and diaﬁltration of the precipitate particles were found
o replace the commonly used centrifugation method. In this
pproach, the individual precipitate ﬂocs are preserved, resulting in
apid dissolution of the precipitate. Increase in HMWI  during pre-
ipitate recovery by TFF can be minimized by reducing the time to
hear exposure. This can be accomplished by either increasing the
F cartridge size and/or using lower concentration factors. Higher
iters further help overcome this limitation. As precipitates readily
issolve in various buffer systems, which are used as loading buffers
n mixed-mode or ion exchange chromatography, this step can be
oupled with subsequent puriﬁcation steps. Steps not contribut-
ng to the purity such as ultra-/diaﬁltration, required to condition
he solution for a next puriﬁcation step, can be eliminated. The
lightly higher viscosity due to residual PEG at low concentrations
resent after mAb  precipitate resolubilization does not affect sub-
equent unit operations. Residual PEG (3350) has been shown not to
nterfere with subsequent cation exchange chromatographic steps
2,16]. CD spectroscopy did not reveal any changes in the secondary
tructure of the mAb  compared with the chromatographically puri-
[ mg/ml  of the mAb  precipitate was diluted in the respective buffers to reach a ﬁnal
ﬁed reference material, neither due to the phase change during
precipitation nor due to the recovery by TFF.
The sequential precipitation presented has several advantages
over the classical PEG precipitation approach, without further com-
plicating the process. Combined with a TFF-based mAb precipitate
recovery, this capture step unites advantages with regard to the use
of single-use equipment and continuous processing.
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